{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:51:59Z","timestamp":1774864319704,"version":"3.50.1"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bioorg.2026.109757","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:05:37Z","timestamp":1773504337000},"page":"109757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis and docking studies of new benzothiophene and benzothienopyran derivatives as topoisomerase I inhibitors with potential immunomodulatory action via cGAS\u2013STING signaling pathway"],"prefix":"10.1016","volume":"174","author":[{"given":"Shimaa M.","family":"Alhamaky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia A.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa S.A.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Osama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora M.","family":"Aborehab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaymaa G.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa A.","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2026.109757_bb0005","first-page":"7","article-title":"Cancer statistics","volume":"72","author":"Siegel","year":"2022","journal-title":"CA A Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109757_bb0010","first-page":"70","article-title":"The side effects of chemotherapeutic agents","volume":"19","author":"Ng","year":"2008","journal-title":"Current anesthesia Crit. Care"},{"key":"10.1016\/j.bioorg.2026.109757_bb0015","first-page":"539","article-title":"Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy","volume":"54","author":"Husain","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109757_bb0020","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0167-4781(95)00171-9","article-title":"Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung","volume":"1264","author":"Giaccone","year":"1995","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bioorg.2026.109757_bb0025","doi-asserted-by":"crossref","unstructured":"T.D. Pfister, W.C. Reinhold, K. Agama, S. Gupta, S.A. Khin, R.J. Kinders, R.E. Parchment, J.E. Tomaszewski, J.H. Doroshow, Y. Pommier, Mol, Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity, Canc. Ther. 8 (2009) 1878\u20131884.","DOI":"10.1158\/1535-7163.MCT-09-0016"},{"key":"10.1016\/j.bioorg.2026.109757_bb0030","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1158\/0008-5472.CAN-09-3528","article-title":"Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron","volume":"70","author":"Reinhold","year":"2010","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109757_bb0035","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA topoisomerases: structure, function, and mechanism","volume":"70","author":"Champoux","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bioorg.2026.109757_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104551","article-title":"Topoisomerase inhibitors: pharmacology and emerging nanoscale delivery systems","volume":"151","author":"Dehshahri","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.109757_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104915","article-title":"Synthesis, molecular modeling and biological evaluation of new benzo [4, 5] thieno [3, 2-b] pyran derivatives as topoisomerase I-DNA binary complex poisons","volume":"112","author":"Ahmed","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109757_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106638","article-title":"New benzothienopyran and benzothienopyranopyrimidine derivatives as topoisomerase I inhibitors: design, synthesis, anticancer screening, apoptosis induction and molecular modeling studies","volume":"137","author":"Khalil","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109757_bb0055","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev.bi.58.070189.002031","article-title":"DNA topoisomerase poisons as antitumor drugs","volume":"58","author":"Liu","year":"1989","journal-title":"Annu. Rev. Biochem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109757_bb0060","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109757_bb0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2026.109757_bb0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/10428199409051674","article-title":"Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells","volume":"15","author":"Solary","year":"1994","journal-title":"Leuk. Lymphoma"},{"issue":"1\u20133","key":"10.1016\/j.bioorg.2026.109757_bb0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0167-4781(98)00136-5","article-title":"Cell death induced by topoisomerase-targeted drugs: more questions than answers","volume":"1400","author":"Kaufmann","year":"1998","journal-title":"Biochim. Biophys. Acta Gene Struct. Expr."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109757_bb0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/1568011033482378","article-title":"Apoptosis induced by topoisomerase inhibitors","volume":"3","author":"Sordet","year":"2003","journal-title":"Curr. Med. Chem. Anticancer Agents"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109757_bb0085","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.cell.2005.05.019","article-title":"Apoptotic pathways: ten minutes to dead","volume":"121","author":"Green","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109757_bb0090","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/nrc2465","article-title":"The TRAIL apoptotic pathway in cancer onset, progression and therapy","volume":"8","author":"Johnstone","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109757_bb0095","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrm2312","article-title":"Apoptosis: controlled demolition at the cellular level","volume":"9","author":"Taylor","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109757_bb0100","series-title":"DNA Topoisomerases and Cancer","first-page":"409","article-title":"Topoisomerases and apoptosis","author":"Sordet","year":"2011"},{"issue":"10","key":"10.1016\/j.bioorg.2026.109757_bb0105","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/sj.leu.2401902","article-title":"Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies","volume":"14","author":"Solary","year":"2000","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109757_bb0110","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood.V97.12.3931","article-title":"Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis","volume":"97","author":"Sordet","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109757_bb0115","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1099320","article-title":"The pathophysiology of mitochondrial cell death","volume":"305","author":"Green","year":"2004","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109757_bb0120","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","article-title":"The BCL-2 family Reunion","volume":"37","author":"Chipuk","year":"2010","journal-title":"Mol. Cell"},{"issue":"9","key":"10.1016\/j.bioorg.2026.109757_bb0125","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrm2952","article-title":"Mitochondria and cell death: outer membrane permeabilization and beyond","volume":"11","author":"Tait","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109757_bb0130","doi-asserted-by":"crossref","unstructured":"Hsu, Y.T., Wolter, K.G. and Youle, R.J., 1997. Cytosol-to-membrane redistribution of Bax and Bcl-XL during apoptosis. Proc. Natl. Acad. Sci., 94(8) (1997) 3668\u20133672.","DOI":"10.1073\/pnas.94.8.3668"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109757_bb0135","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1128\/MCB.20.3.929-935.2000","article-title":"Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane","volume":"20","author":"Eskes","year":"2000","journal-title":"Mol. Cell. Biol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109757_bb0140","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1101\/gad.14.16.2060","article-title":"tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c","volume":"14","author":"Wei","year":"2000","journal-title":"Genes Dev."},{"issue":"1\u20133","key":"10.1016\/j.bioorg.2026.109757_bb0145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-4781(98)00135-3","article-title":"DNA sequence selectivity of topoisomerases and topoisomerase poisons","volume":"1400","author":"Capranico","year":"1998","journal-title":"Biochim. Biophys. Acta (BBA)-Gene Structure and Expression"},{"key":"10.1016\/j.bioorg.2026.109757_bb0150","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"15","key":"10.1016\/j.bioorg.2026.109757_bb0155","first-page":"1504","article-title":"Topoisomerase II inhibitors and poisons, and the influence of cell cycle checkpoints","volume":"24","author":"Arcy","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109757_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107431","article-title":"Recent developments of topoisomerase inhibitors: clinical trials, emerging indications, novel molecules and global sales","volume":"209","author":"Bondarev","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.109757_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119791","article-title":"Targeted camptothecin delivery via silicon nanoparticles reduces breast cancer metastasis","volume":"240","author":"Landgraf","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioorg.2026.109757_bb0170","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1073\/pnas.92.19.8861","article-title":"Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites proc","volume":"92","author":"Pommier","year":"1995","journal-title":"Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109757_bb0175","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/gutjnl-2012-302410","article-title":"Metronomic topotecan for colorectal cancer: a promising new option","volume":"62","author":"Wang","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.bioorg.2026.109757_bb0180","doi-asserted-by":"crossref","unstructured":"D.C. Bodurka, C. Levenback, J.K. Wolf, J. Gano, J.T. Wharton, J.J., Kavanagh, D.M. Gershenson, Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J. Clin. Oncol., 21(2) (2003) 291\u2013297.","DOI":"10.1200\/JCO.2003.02.091"},{"key":"10.1016\/j.bioorg.2026.109757_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17111414","article-title":"Camptothecin in cancer therapy: current challenges and emerging strategies with nanoemulsions","volume":"17","author":"P\u00e9rez-Ortega","year":"2025","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109757_bb0190","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1021\/jm9803323","article-title":"Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons","volume":"42","author":"Strumberg","year":"1999","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109757_bb0195","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1158\/1535-7163.MCT-08-0706","article-title":"The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives","volume":"8","author":"Pommier","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"24","key":"10.1016\/j.bioorg.2026.109757_bb0200","doi-asserted-by":"crossref","first-page":"8716","DOI":"10.1021\/jm101048k","article-title":"Design, synthesis, and evaluation of dibenzo [c, h][1, 6] naphthyridines as topoisomerase I inhibitors and potential anticancer agents","volume":"53","author":"Kiselev","year":"2010","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109757_bb0205","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0014-827X(03)00042-9","article-title":"Some new bi-and ter-benzimidazole derivatives as topoisomerase I inhibitors","volume":"58","author":"Alper","year":"2003","journal-title":"Il Farmaco"},{"key":"10.1016\/j.bioorg.2026.109757_bb0210","doi-asserted-by":"crossref","unstructured":"E. Oksuzoglu, B. Tekiner-Gulbas, S. Alper, O. Temiz-Arpaci, T. Ertan, I, Yildiz, N. Diril, E. Sener-Aki, I. Yalcin, Some benzoxazoles and benzimidazoles as DNA topoisomerase I and II inhibitors. J. Enz. Inhib. Med. Chem. 23(1) (2008) 37\u201342.","DOI":"10.1080\/14756360701342516"},{"issue":"42","key":"10.1016\/j.bioorg.2026.109757_bb0215","doi-asserted-by":"crossref","first-page":"27668","DOI":"10.1074\/jbc.273.42.27668","article-title":"The mechanism of inhibition of topoisomerase IV by quinolone antibacterials","volume":"273","author":"Khodursky","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109757_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010186","article-title":"Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II","volume":"5","author":"Hawtin","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2026.109757_bb0225","doi-asserted-by":"crossref","unstructured":"K.M. Heinhuis, W. Ros, M. Kok, N. Steeghs, J.H. Beijnen, J.H.M. Schellens, 2019. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann. Oncol., 30(2) (2019) 219\u2013235.","DOI":"10.1093\/annonc\/mdy551"},{"issue":"8","key":"10.1016\/j.bioorg.2026.109757_bb0230","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00262-013-1431-9","article-title":"The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells","volume":"62","author":"Trojandt","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bioorg.2026.109757_bb0235","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1021\/jm049146p","article-title":"Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex","volume":"48","author":"Staker","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109757_bb0240","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.molcel.2023.12.005","article-title":"cGAS goes viral: a conserved immune defense system from bacteria to humans","volume":"84","author":"Jenson","year":"2024","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.109757_bb0245","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaa2630","article-title":"Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation","volume":"347","author":"Liu","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109757_bb0250","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.molcel.2014.03.040","article-title":"The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling","volume":"54","author":"Cai","year":"2014","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109757_bb0255","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.4049\/jimmunol.1601694","article-title":"DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity","volume":"198","author":"Kitai","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.bioorg.2026.109757_bb0260","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41416-022-01894-4","article-title":"Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS\/STING pathway","volume":"127","author":"Marinello","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109757_bb0265","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/40901","article-title":"X-linked IAP is a direct inhibitor of cell-death proteases","volume":"388","author":"Deveraux","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109757_bb0270","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1097-2765(03)00054-6","article-title":"Mechanism of XIAP-mediated inhibition of caspase-9","volume":"11","author":"Shiozaki","year":"2003","journal-title":"Mol. Cell."},{"key":"10.1016\/j.bioorg.2026.109757_bb0275","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/35065125","article-title":"A conserved XIAP-interaction motif in caspase-9 and Smac\/DIABLO regulates caspase activity and apoptosis","volume":"410","author":"Srinivasula","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109757_bb0280","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1093\/emboj\/17.8.2215","article-title":"IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases","volume":"17","author":"Deveraux","year":"1998","journal-title":"EMBO J."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109757_bb0285","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/emboj\/20.5.998","article-title":"Recruitment, activation and retention of caspases-9 and -3 by Apaf-1 apoptosome and associated XIAP complexes","volume":"20","author":"Bratton","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.bioorg.2026.109757_bb0290","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1158\/1078-0432.CCR-13-0227","article-title":"Molecular pathways: targeting inhibitor of apoptosis proteins in cancer\u2014from molecular mechanism to therapeutic application","volume":"20","author":"Fulda","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109757_bb0295","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1038\/onc.2008.302","article-title":"IAP-targeted therapies for cancer","volume":"27","author":"LaCasse","year":"2008","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109757_bb0300","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1128\/JVI.05989-11","article-title":"I\u03baB kinase \u03b5-dependent phosphorylation and degradation of X-linked inhibitor of apoptosis sensitizes cells to virus-induced apoptosis","volume":"86","author":"Nakhaei","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.bioorg.2026.109757_bb0305","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/jpet.109.159962","article-title":"Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and Survivin thereby activating Caspase-3-mediated bid cleavage","volume":"332","author":"Tomicic","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2026.109757_bb0310","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2147\/CMAR.S160924","article-title":"Andrographolide potentiates the antitumor effect of topotecan in acute myeloid leukemia cells through an intrinsic apoptotic pathway","volume":"10","author":"Hodroj","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.bioorg.2026.109757_bb0315","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1158\/2767-9764.CRC-23-0082","article-title":"Targeted degradation of XIAP is sufficient and specific to induce apoptosis in MYCN-overexpressing high-risk neuroblastoma","volume":"3","author":"Choo","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.bioorg.2026.109757_bb0320","series-title":"Cancer Drug Discovery and Development: Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials and Approval","first-page":"41","article-title":"The NCI human tumor cell line (60-cell) screen","author":"Boyd","year":"2014"},{"key":"10.1016\/j.bioorg.2026.109757_bb0325","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jnci\/83.11.757","article-title":"Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines","volume":"83","author":"Monks","year":"1991","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bioorg.2026.109757_bb0330","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bioorg.2026.109757_bb0335","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109757_bb0340","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/met13040735","article-title":"Au\/ZnO nanocomposites prepared by laser ablation for enhancement of antibacterial activity and cytotoxic properties against cancer cells","volume":"13","author":"Alhujaily","year":"2023","journal-title":"Metals"},{"key":"10.1016\/j.bioorg.2026.109757_bb0345","doi-asserted-by":"crossref","DOI":"10.1063\/5.0000161","article-title":"Therapeutic combination of gold nanoparticles and LPS as cytotoxic and apoptosis inducer in breast cancer cells","volume":"2213","author":"Sameen","year":"2020","journal-title":"AIP Conf. Proc."},{"key":"10.1016\/j.bioorg.2026.109757_bb0350","doi-asserted-by":"crossref","first-page":"32950","DOI":"10.1074\/jbc.274.46.32950","article-title":"A functional linker in human topoisomerase I is required for maximum sensitivity to Camptothecin in a DNA relaxation assay","volume":"274","author":"Stewart","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2026.109757_bb0355","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: fast, flexible, and free","volume":"26","author":"Van Der Spoel","year":"2005","journal-title":"J. Comput. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109757_bb0360","doi-asserted-by":"crossref","first-page":"641a","DOI":"10.1016\/j.bpj.2015.11.3431","article-title":"CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field","volume":"110","author":"Lee","year":"2016","journal-title":"Biophys. J."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109757_bb0365","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jcc.21367","article-title":"CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields","volume":"31","author":"Vanommeslaeghe","year":"2010","journal-title":"J. Comput. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826002932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826002932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:53:12Z","timestamp":1774860792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826002932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":73,"alternative-id":["S0045206826002932"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109757","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and docking studies of new benzothiophene and benzothienopyran derivatives as topoisomerase I inhibitors with potential immunomodulatory action via cGAS\u2013STING signaling pathway","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109757"}}